Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked results being generally positive, concerns about Moderna's high valuation and future growth prospects led to the sell-off. The stock had surged nearly 700% year-to-date before this correction but remains significantly up overall. Merck, a partner on the vaccine, also saw a smaller decline in its shares. Investors will be watching for further trial updates and market reactions to gauge Moderna's long-term outlook.
Moderna's stock price on Pluang is currently USD 193.84, down 4.34% as of Oct 23, 2026 17:11 WIB, trading well below its 52-week high of USD 245.81 but far above its 52-week low of USD 22.36. In contrast, Merck's shares have declined only 0.78% to USD 146.09, closer to its 52-week high of USD 156.43 than to its low of USD 82.49. Pluang order activity shows a heavier sell sentiment for Moderna at 71% compared to 63% for Merck, reflecting more cautious positioning among investors on the platform.
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
Moderna's stock fell sharply by 25% following an unauthorized leak of Phase 3 data for its experimental cancer vaccine developed with Merck. The data was expected to be officially presented at a medical conference this weekend. Merck's shares also de...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
Moderna, known for its mRNA COVID-19 vaccine, is set to reveal full Phase 3 data for its experimental cancer vaccine targeting melanoma. The results, expected this weekend, could mark a breakthrough in cancer treatment using customized mRNA technolog...
